Early rituximab treatment in children with idiopathic nephrotic syndrome Eng. ERICONS - Early RITUXIMAB in Childhood Onset Nephrotic Syndrome

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515058-26-00

Acronym

NBK155/1/2020

Enrollment

Registered

2024-11-07

Start date

2021-12-17

Completion date

Unknown

Last updated

2025-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NEPHROTIC SYNDROME

Brief summary

Relapse-free survival (defined as the occurrence of proteinuria persisting for ≥ 3 days during the blinded phase (from day 1 to day 365)).

Detailed description

Time to treatment failure 1a. Percentage of failures in the experimental and placebo groups., Total dose of administered steroids., Time from depletion resolution to relapse., Relapse-free survival during the open-label phase (from the day of investigational drug administration to day 365 of observation).

Interventions

DRUGMabThera 100 mg concentrate for solution for infusion

DRUGSaline

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
Relapse-free survival (defined as the occurrence of proteinuria persisting for ≥ 3 days during the blinded phase (from day 1 to day 365)).	—

Secondary

Measure	Time frame
Time to treatment failure 1a. Percentage of failures in the experimental and placebo groups., Total dose of administered steroids., Time from depletion resolution to relapse., Relapse-free survival during the open-label phase (from the day of investigational drug administration to day 365 of observation).	—

Countries

Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026